StarZero All shows Try the podcast clipper →

Carlos Araya

Founder, Tapanti.org · 2 appearances on the record.

computed by AI from the episodes · how this works → · full disclaimer →

founderexecutivescientisttapanti.org ↗

Carlos L. Araya is an entrepreneur and scientist who co-founded and served as CEO of Jungla Inc., a biotechnology startup that developed computational modeling engines to interpret genetic variants. Jungla was acquired by Invitae Corporation in 2019, integrating its clinical variant modeling technology into genetic diagnostics.

6statements → 6claims → 4claims resolved → 50%fully supported → 3.33/5average certainty → 1.83/5average debate potential →

2 supported 0 partly supported 2 contradicted 2 not checkable as stated how the 6 claims stand · each chip opens the sources

6 assertions · every statement was checked. The predictions and assertions are the 6 claims: statements the public record can support or contradict. 4 are resolved, and 2 name no date, number or outcome precise enough to check. Everything else (opinions, insights, what ifs, disclosures) can never be settled by the record, so it carries no assessment.

The record, in short

What the tape says about how Carlos argues and how the claims held up. Everything they said, and everything said about them, is in the tabs below.

Their most notable supported claim

Assertion Supported
Interpreting novel genetic variants costs 100x to 1000x more than sequencing
“And interpreting each one of those under the current clinical practices costs 50 to a hundred dollars. So we're talking about a hundred to thousand-fold increase in the cost of interpretation relative to the cost of data acquisition.”
Carlos Araya Jan 2, 2019 ▶ 2:59 a16z Podcast | Revisiting the Gene

Their most notable contradicted claim

Assertion Contradicted
Araya: Cancer gene tests find 95 unknown mutations per known mutation
“Those tests will basically find 95 mutations that they have absolutely no clue of what the effects of those mutations are in these important cancer-associated genes per each mutation that is known to cause disease.”
Carlos Araya Jan 2, 2019 ▶ 21:04 a16z Podcast | When Will Genomics Live Up to the Hype?

Expressed certainty vs assessment result

none yet certainty 1
none yet certainty 2
50% certainty 3
50% certainty 4
none yet certainty 5

weighted support: a fully supported claim counts one, a partly supported claim counts half. Each filled bar is clickable and opens exactly those claims; "none yet" means nothing said at that certainty level has resolved yet

Everything Carlos Araya said on the a16z Podcast that made the record, most notable first. Filter by type, assessment or year in the ledger →

Assertion Supported
Interpreting novel genetic variants costs 100x to 1000x more than sequencing
“And interpreting each one of those under the current clinical practices costs 50 to a hundred dollars. So we're talking about a hundred to thousand-fold increase in the cost of interpretation relative to the cost of data acquisition.”
Carlos Araya Jan 2, 2019 ▶ 2:59 a16z Podcast | Revisiting the Gene
Assertion Supported
Only 0.6% of disease-associated gene mutations have clinical interpretations
“If we look across all of the disease-associated genes that we know today, we only have clinical interpretations for roughly . Six percent of the possible mutations in them.”
Carlos Araya Jan 2, 2019 ▶ 3:52 a16z Podcast | Revisiting the Gene
Assertion Contradicted
Araya: Cancer gene tests find 95 unknown mutations per known mutation
“Those tests will basically find 95 mutations that they have absolutely no clue of what the effects of those mutations are in these important cancer-associated genes per each mutation that is known to cause disease.”
Carlos Araya Jan 2, 2019 ▶ 21:04 a16z Podcast | When Will Genomics Live Up to the Hype?
Assertion Not checkable as stated
Araya: DNA sequencing is the second-fastest advancing technology in history
“We've done a pretty good job at being able to acquire sequence information. That's, you know, some of the fastest advances in technology in the history of mankind. I'm told it's actually only beat by one other technology, which is the sort of the clarity of gl…”
Carlos Araya Jan 2, 2019 ▶ 6:43 a16z Podcast | When Will Genomics Live Up to the Hype?
Assertion Not checkable as stated
Araya: Existing genomic maps lack the functional data needed for applications
“Unfortunately the maps that we have today are really maps of function that just say where things that are, things like genes, biomolecules, where they are encoded in the genome, but it says really nothing about how they function and which parts of the genes do…”
Carlos Araya Jan 2, 2019 ▶ 7:27 a16z Podcast | When Will Genomics Live Up to the Hype?
Assertion Contradicted
Each sequenced genome contains about 100 novel variants in disease genes
“Although there are three million variants identified, There will be roughly a hundred variants that are novel variants in disease-associated genes.”
Carlos Araya Jan 2, 2019 ▶ 2:48 a16z Podcast | Revisiting the Gene

Appearances (2)

EpisodeDateSpeaking time
a16z Podcast | Revisiting the Gene Jan 2, 2019 3m
a16z Podcast | When Will Genomics Live Up to the Hype? Jan 2, 2019 5m
Made with StarZero

Turn any episode into a week of clips.

This entire site, over 1,000 episodes transcribed, diarized, checked and made playable, runs on the StarZero media pipeline. Drop in your own episode and the podcast clipper finds the moments worth sharing, cuts them, captions them, and reframes them for every feed.

Try the podcast clipper Learn more